CTNNB1 and breast cancer: However, addition of CS-E treatment to Wnt3a stimulation severely reduced nuclear beta-catenin expression levels (Figure 4A), suggesting that CS-E, but not C4S, is a potent inhibitor of Wnt/beta-catenin signaling in breast cancer cells.